DCVax-Direct: Additional Phase I/II data

Northwest Biotherapeutics said 27 of 39 evaluable patients with advanced, inoperable solid tumors who received intratumoral DCVax-Direct in the Phase I portion of an open-label, U.S. Phase I/II trial ...